Insights

Home » Insights » Insights Intercept Blood System
    08/2018- Economics

    INTERCEPT Blood System further expands with  the TS  multidose set (video)

    In Europe, 40% of all platelet concentrates undergo either bacterial screening or pathogen inactivation. This percentage may increase even more in 2018 as major European countries are currently taking action to mitigate the risk of septic transfusion reactions and emerging pathogens. 


    07/2018- Economics

    The economics of Double Dose Buffy Coat Platelets

    For blood centres seeking a cost-effective way to implement INTERCEPT pathogen inactivation, double dose buffy coat platelet production may offer a solution.

    What is a double dose buffy coat platelet unit?

    A platelet concentrate with sufficient platelet count to result in 2 therapeutic doses after pathogen inactivation with the INTERCEPT Blood System.

    The double dose buffy coat platelet...